WIRE — Brokerages have retained their ratings but highlighted concerns over the delay in semaglutide commercialisation following an API impurity issue disclosed by the company during its earnings call.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.